Syros Pharmaceuticals Inc (SYRS) Receives $26.14 Average Target Price from Analysts

Syros Pharmaceuticals Inc (NASDAQ:SYRS) has been assigned an average rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $26.14.

Several research firms have recently issued reports on SYRS. Oppenheimer set a $28.00 target price on Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Cann restated a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Zacks Investment Research lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Finally, JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective on the stock in a report on Thursday, September 28th.

Syros Pharmaceuticals (NASDAQ SYRS) traded down $0.39 during trading on Thursday, hitting $9.50. The stock had a trading volume of 278,300 shares, compared to its average volume of 137,955. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). equities research analysts predict that Syros Pharmaceuticals will post -2.12 earnings per share for the current fiscal year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju acquired 109,774 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were acquired at an average price of $9.03 per share, for a total transaction of $991,259.22. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were acquired at an average price of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Insiders own 33.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in SYRS. Nationwide Fund Advisors lifted its holdings in shares of Syros Pharmaceuticals by 249.8% during the 2nd quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock valued at $113,000 after purchasing an additional 5,016 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Syros Pharmaceuticals in the 3rd quarter valued at approximately $133,000. Cubist Systematic Strategies LLC bought a new stake in Syros Pharmaceuticals in the 3rd quarter valued at approximately $149,000. The Manufacturers Life Insurance Company lifted its stake in Syros Pharmaceuticals by 11,253.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after acquiring an additional 10,466 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Syros Pharmaceuticals in the 2nd quarter valued at approximately $198,000. Institutional investors and hedge funds own 57.96% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/12/19/syros-pharmaceuticals-inc-syrs-receives-26-14-average-target-price-from-analysts.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

What are top analysts saying about Syros Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Syros Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit